This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Biosimilars: overview

As potential alternatives to originator biologics, biosimilars may expand treatment options to meet the growing demand for biologic therapies1

By providing potentially more cost-effective treatment options, biosimilars may allow for the reallocation of resources to other areas of patient care, while still delivering quality and effective results1,2

There is the potential for improved outcomes as a result of earlier treatment with biologics3

  • This is made possible by reducing costs, which may increase access to biosimilars compared with access to originator biologics3

As existing biologic medicines lose marketing exclusivity, biosimilar medicines may become increasingly important for managing difficult-to-treat diseases in a more cost-effective manner1

From 2006 to 2017, the use of biosimilars in the five major EU markets* has been attributed to cost savings of €1.5 billion to healthcare systems4
France, Germany, Italy, Spain and the UK.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. 2016. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf. Accessed May 2023.Gulácsi L, et al. Expert Rev Clin Immunol 2015;11(suppl 1):S43-S52.Uhlig T, Goll GL. Rheumatology 2017;56(Suppl 4):iv49-iv62.Medicines for Europe. Medicines for Europe country specific market access policies. 2017. Available at: http://www.medicinesforeurope.com/wp-content/uploads/2017/05/20170220-Medicines-for-Europe-recommendationsv1.0_FINAL.pdf. Accessed May 2023.Henry D, Taylor C. Semin Oncol 2014;41(Suppl 3):S13-S20.
Biosimilars
Support & Resources

Pfizer has a range of resources available to support you and your patients

ExploreLoading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0145 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024